IL320743A - Method of treating prostate cancer - Google Patents

Method of treating prostate cancer

Info

Publication number
IL320743A
IL320743A IL320743A IL32074325A IL320743A IL 320743 A IL320743 A IL 320743A IL 320743 A IL320743 A IL 320743A IL 32074325 A IL32074325 A IL 32074325A IL 320743 A IL320743 A IL 320743A
Authority
IL
Israel
Prior art keywords
prostate cancer
treating prostate
treating
cancer
prostate
Prior art date
Application number
IL320743A
Other languages
Hebrew (he)
Inventor
Michael D Groaning
Richard Messmann
Michael J Morris
Alton Oliver Sartor
Original Assignee
Novartis Ag
Michael D Groaning
Richard Messmann
Michael J Morris
Alton Oliver Sartor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/448,609 external-priority patent/US20240197926A1/en
Application filed by Novartis Ag, Michael D Groaning, Richard Messmann, Michael J Morris, Alton Oliver Sartor filed Critical Novartis Ag
Publication of IL320743A publication Critical patent/IL320743A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL320743A 2022-12-05 2023-12-04 Method of treating prostate cancer IL320743A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263386040P 2022-12-05 2022-12-05
US18/448,609 US20240197926A1 (en) 2022-12-05 2023-08-11 Method of treating prostate cancer
US202363592377P 2023-10-23 2023-10-23
PCT/IB2023/062204 WO2024121722A1 (en) 2022-12-05 2023-12-04 Method of treating prostate cancer

Publications (1)

Publication Number Publication Date
IL320743A true IL320743A (en) 2025-07-01

Family

ID=89222088

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320743A IL320743A (en) 2022-12-05 2023-12-04 Method of treating prostate cancer

Country Status (9)

Country Link
EP (1) EP4630063A1 (en)
JP (1) JP2025541733A (en)
KR (1) KR20250116127A (en)
CN (1) CN120303009A (en)
AU (1) AU2023389426A1 (en)
IL (1) IL320743A (en)
MX (1) MX2025006427A (en)
TW (1) TW202440171A (en)
WO (1) WO2024121722A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof
JPWO2025058000A1 (en) 2023-09-13 2025-03-20
CN121445909A (en) * 2026-01-04 2026-02-03 润方(北京)生物医药研究院有限公司 Application of hemoglobin oxygen carrier combined with radionuclide drug in treating prostate cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013610A1 (en) 2000-08-17 2002-02-21 Mirus Corporation Nucleic acid expression from linear nucleic acids
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
JP2023539990A (en) 2020-07-13 2023-09-21 ポイント バイオファーマ インコーポレイテッド Radiopharmaceuticals and methods

Also Published As

Publication number Publication date
EP4630063A1 (en) 2025-10-15
TW202440171A (en) 2024-10-16
CN120303009A (en) 2025-07-11
KR20250116127A (en) 2025-07-31
JP2025541733A (en) 2025-12-23
WO2024121722A1 (en) 2024-06-13
MX2025006427A (en) 2025-09-02
AU2023389426A1 (en) 2025-05-15

Similar Documents

Publication Publication Date Title
IL320332A (en) Methods for treating cancer
EP4111202A4 (en) Methods of treating cancer
IL320962A (en) Methods of treating advanced solid tumors
IL289811A (en) Method of treating cancer
IL325326A (en) Method of treating cancer with indoline inhibitors of kif18a
IL326327A (en) Prostate cancer treatment
IL325454A (en) Method of treating prostate cancer
IL314798A (en) Methods of treating prostate cancer
IL312155A (en) Method of cancer treatment
IL272390A (en) Methods of treating cancer
CA3274501A1 (en) Method of treating prostate cancer
IL315569A (en) Methods of treating cancer
HK40122526A (en) Methods of treating prostate cancer
HK40087831A (en) Methods of treating prostate cancer
IL312332A (en) Methods of treating cancer
IL320448A (en) Methods of treating cancer with sotorasib
CA3297160A1 (en) Method for treating prostate cancer
CA3265149A1 (en) Methods of treating prostate cancer using exicorilant and enzalutamide
GB202412414D0 (en) Methods for treating cancer
IL326216A (en) Combination therapy for prostate cancer
GB202013074D0 (en) Method of treatment for cancer
CA3310617A1 (en) Methods of treating cancer
AU2024377510A1 (en) Methods of treating cancer
CA3293232A1 (en) Methods of treating cancer
GB202006474D0 (en) Method of treatment of cancer or tumour